The impact of harboring an EGFR mutation was evaluated in a study by Tanaka et al. In this study, the group assessed the effect of EGFR mutation status on progression-free survival in those with stage III NSCLC treated with chemo-radiotherapy. Here, EGFR is linked to non-small cell lung carcinoma.